AUSTIN, Texas (AP) ¿ Luminex Corp. on Friday said that the U.S. Food and Drug Administration has given approval for the company's new cystic fibrosis test. The test detects for 39 gene mutations that cause cystic fibrosis, the company said. It can be used for diagnosis or to screen potential parents to determine if they are carriers for the disease-causing gene mutations. Shares of Luminex rose 76 cents to $15.62 in afternoon trading Friday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Food & Drink
Blue Apron Seeks a Reverse Stock Split to Retain its Listing
Blue Apron debuted about two years ago. But It faces being delisted below the $1 threshold.
Beyond Meat Slides After Andrew Left's Citron Slams Stock in Tweet
Newly public meat-alternative company sees shares lower on short-seller's critique.
PepsiCo Still Looks Bullish - A Higher Price Target Seen
How do the charts look with their latest advance?